Emi Kimoto

List of Publications by Year
in descending order

35 papers	2,030 citations	304743 22 h-index	361022 35 g-index
37 all docs	37 docs citations	37 times ranked	1893 citing authors

#	Article	IF	Citations
1	Classification of Inhibitors of Hepatic Organic Anion Transporting Polypeptides (OATPs): Influence of Protein Expression on Drugâ€“Drug Interactions. Journal of Medicinal Chemistry, 2012, 55, 4740-4763.	6.4	299
2	Mechanistic Pharmacokinetic Modeling for the Prediction of Transporter-Mediated Disposition in Humans from Sandwich Culture Human Hepatocyte Data. Drug Metabolism and Disposition, 2012, 40, 1007-1017.	3.3	228
3	Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19. Nature Communications, 2021, 12, 6055.	12.8	215
4	Mechanistic Modeling to Predict the Transporter- and Enzyme-Mediated Drug-Drug Interactions of Repaglinide. Pharmaceutical Research, 2013, 30, 1188-1199.	3.5	96
5	Characterization of Organic Anion Transporting Polypeptide (OATP) Expression and Its Functional Contribution to the Uptake of Substrates in Human Hepatocytes. Molecular Pharmaceutics, 2012, 9, 3535-3542.	4.6	94
6	Quantitative assessment of the contribution of sodiumâ€dependent taurocholate coâ€transporting polypeptide (NTCP) to the hepatic uptake of rosuvastatin, pitavastatin and fluvastatin. Biopharmaceutics and Drug Disposition, 2013, 34, 452-461.	1.9	72
7	Doseâ€Dependent Inhibition of OATP1B by Rifampicin in Healthy Volunteers: Comprehensive Evaluation of Candidate Biomarkers and OATP1B Probe Drugs. Clinical Pharmacology and Therapeutics, 2020, 107, 1004-1013.	4.7	66
8	Quantitative Rationalization of Gemfibrozil Drug Interactions: Consideration of Transporters-Enzyme Interplay and the Role of Circulating Metabolite Gemfibrozil 1-O-Î²-Glucuronide. Drug Metabolism and Disposition, 2015, 43, 1108-1118.	3.3	65
9	Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans. Drug Metabolism and Disposition, 2022, 50, 576-590.	3.3	64
10	Quantitative Prediction of Transporter- and Enzyme-Mediated Clinical Drug-Drug Interactions of Organic Anion-Transporting Polypeptide 1B1 Substrates Using a Mechanistic Net-Effect Model. Journal of Pharmacology and Experimental Therapeutics, 2014, 351, 214-223.	2.5	61
11	Hepatobiliary Clearance Prediction: Species Scaling From Monkey, Dog, and Rat, and InÂVitroâ€“InÂVivo Extrapolation of Sandwich-Cultured Human Hepatocytes Using 17 Drugs. Journal of Pharmaceutical Sciences, 2017, 106, 2795-2804.	3.3	59
12	Quantitative Contribution of Six Major Transporters to the Hepatic Uptake of Drugs: â€œSLC-Phenotypingâ€• Using Primary Human Hepatocytes. Journal of Pharmacology and Experimental Therapeutics, 2019, 370, 72-83.	2.5	58
13	PBPK Modeling of Coproporphyrin I as an Endogenous Biomarker for Drug Interactions Involving Inhibition of Hepatic OATP1B1 and OATP1B3. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 739-747.	2.5	51
14	Quantitative Proteomics and Mechanistic Modeling of Transporterâ€Mediated Disposition in Nonalcoholic Fatty Liver Disease. Clinical Pharmacology and Therapeutics, 2020, 107, 1128-1137.	4.7	51
15	Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability â€“ considerations for drug development. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 723-743.	3.3	49
16	Organic Anion Transporter 2â€“Mediated Hepatic Uptake Contributes to the Clearance of High-Permeabilityâ€“Low-Molecular-Weight Acid and Zwitterion Drugs: Evaluation Using 25 Drugs. Journal of Pharmacology and Experimental Therapeutics, 2018, 367, 322-334.	2.5	44
17	Physiologicallyâ€Based Pharmacokinetic Modeling Approach to Predict Rifampinâ€Mediated Intestinal Pâ€Glycoprotein Induction. CPT: Pharmacometrics and Systems Pharmacology, 2019, 8, 634-642.	2.5	41
18	Reliable Rate Measurements for Active and Passive Hepatic Uptake Using Plated Human Hepatocytes. AAPS Journal, 2017, 19, 787-796.	4.4	39

#	Article	IF	Citations
19	Characterization of Digoxin Uptake in Sandwich-Cultured Human Hepatocytes. Drug Metabolism and Disposition, 2011, 39, 47-53.	3.3	38
20	Hepatic Disposition of Gemfibrozil and Its Major Metabolite Gemfibrozil 1-O-Î²-Glucuronide. Molecular Pharmaceutics, 2015, 12, 3943-3952.	4.6	33
21	Identification of Appropriate Endogenous Biomarker for Risk Assessment of Multidrug and Toxin Extrusion Proteinâ€Mediated Drugâ€Drug Interactions in Healthy Volunteers. Clinical Pharmacology and Therapeutics, 2021, 109, 507-516.	4.7	27
22	Comparison of Proteomic Quantification Approaches for Hepatic Drug Transporters: Multiplexed Global Quantitation Correlates with Targeted Proteomic Quantitation. Drug Metabolism and Disposition, 2018, 46, 692-696.	3.3	25
23	Quantitative prediction of breast cancer resistant protein mediated drugâ€drug interactions using physiologicallyâ€based pharmacokinetic modeling. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 1018-1031.	2.5	22
24	Quantification of Hepatic Organic Anion Transport Proteins OAT2 and OAT7 in Human Liver Tissue and Primary Hepatocytes. Molecular Pharmaceutics, 2018, 15, 3227-3235.	4.6	21
25	Biomarkerâ€Informed Modelâ€Based Risk Assessment of Organic Anion Transporting Polypeptide 1B Mediated Drugâ€Drug Interactions. Clinical Pharmacology and Therapeutics, 2022, 111, 404-415.	4.7	21
26	Application of Physiologically Based Pharmacokinetic Modeling in Understanding Bosutinib Drug-Drug Interactions: Importance of Intestinal P-Glycoprotein. Drug Metabolism and Disposition, 2018, 46, 1200-1211.	3.3	19
27	In vitro studies with two human organic anion transporters: OAT2 and OAT7. Xenobiotica, 2018, 48, 1037-1049.	1.1	18
28	Mechanistic Evaluation of the Complex Drug-Drug Interactions of Maraviroc: Contribution of Cytochrome P450 3A, P-Glycoprotein and Organic Anion Transporting Polypeptide 1B1. Drug Metabolism and Disposition, 2019, 47, 493-503.	3.3	17
29	A Study on Pharmacokinetics of Bosentan with Systems Modeling, Part 1: Translating Systemic Plasma Concentration to Liver Exposure in Healthy Subjects. Drug Metabolism and Disposition, 2018, 46, 346-356.	3.3	16
30	Effect of a Ketohexokinase Inhibitor (PFâ€06835919) on In Vivo OATP1B Activity: Integrative Risk Assessment Using Endogenous Biomarker and a Probe Drug. Clinical Pharmacology and Therapeutics, 2022, 112, 605-614.	4.7	11
31	A Study on Pharmacokinetics of Bosentan with Systems Modeling, Part 2: Prospectively Predicting Systemic and Liver Exposure in Healthy Subjects. Drug Metabolism and Disposition, 2018, 46, 357-366.	3.3	9
32	Estimation of Circulating Drug Metabolite Exposure in Human Using In Vitro Data and Physiologically Based Pharmacokinetic Modeling: Example of a High Metabolite/Parent Drug Ratio. Drug Metabolism and Disposition, 2018, 46, 89-99.	3.3	9
33	Evaluation of Hepatic Uptake of OATP1B Substrates by Short Term-Cultured Plated Human Hepatocytes: Comparison With Isolated Suspended Hepatocytes. Journal of Pharmaceutical Sciences, 2021, 110, 376-387.	3.3	8
34	Identification and quantitation of enzyme and transporter contributions to hepatic clearance for the assessment of potential drug-drug interactions. Drug Metabolism and Pharmacokinetics, 2020, 35, 18-29.	2.2	6
35	Cell-to-Medium Concentration Ratio Overshoot in the Uptake of Statins by Human Hepatocytes in Suspension, but Not in Monolayer: Kinetic Analysis Suggesting a Partial Loss of Functional OATP1Bs. AAPS Journal, 2020, 22, 133.	4.4	4